Loss of transforming growth factor-b receptor III (TbRIII) correlates with loss of transforming growth factor-b (TGF-b) responsiveness and suggests a role for dysregulated TGF-b signaling in clear cell renal cell carcinoma (ccRCC) progression and metastasis. Here we identify that for all stages of ccRCC TbRIII expression is downregulated in patient-matched tissue samples and cell lines. We find that this loss of expression is not due to methylation of the gene and we define GATA3 as the first transcriptional factor to positively regulate TbRIII expression in human cells. We localize GATA3 0 s binding to a 10-bp region of the TbRIII proximal promoter. We demonstrate that GATA3 mRNA is downregulated in all stages, of ccRCC, mechanistically show that GATA3 is methylated in ccRCC patient tumor tissues as well as cell lines, and that inhibiting GATA3 expression in normal renal epithelial cells downregulates TbRIII mRNA and protein expression. These data support a sequential model whereby loss of GATA3 expression through epigenetic silencing decreases TbRIII expression during ccRCC progression.
Introduction
Renal cell carcinoma (RCC) accounts for 3% of all malignancies reported each year and is the sixth leading cause of cancer death. Even though localized RCCs can be removed by surgery, B30% of these diagnosed patients will develop metastasis even after nephrectomy (Pantuck et al., 2001) . Incidence of RCC is twice as common in males and usual onset is seen in patients between the ages of 50 and 70 years. The most frequently diagnosed form of the disease is clear cell renal cell carcinoma (ccRCC), which accounts for around 80% of the RCCs diagnosed in the United States. The development of metastasis greatly decreases the survival of ccRCC patients with 5-year survival rates of o10% in patients diagnosed with stage 4 disease (Motzer et al., 1999) . Even though numerous treatments have been tested in addition to surgery, such as radiation, chemotherapy, hormonal therapy, vaccines and immunotherapy, they have all had very little benefit on being able to reduce metastasis (Wood, 2007) . Early diagnosis of this disease is essential for intervention and cure due to the lack of effective treatments available for later stages and metastatic disease.
TbRIII, also known as betaglycan, is the most abundantly expressed transforming growth factor-b (TGF-b) cell surface receptor and shows affinity for all three TGF-b ligand isoforms with highest affinity for binding the TGF-b2 ligand. Although it does not contain a functional kinase domain, TGF-b ligands binding to TbRIII affords presentation of the ligand to the type II TGF-b receptor (TbRII), leading to association and phosphorylation of the type 1 receptor (TbRI), which further phosphorylates Smad2 or Smad3 (reviewed by Elliott and Blobe, 2005; Gordon et al., 2008) . Loss of or reduced TbRIII expression has been observed in human prostate, ovarian, endometrial, pancreas, breast, RCC and lung cancer (Chakravarthy et al., 1999; Copland et al., 2003; Florio et al., 2005; Dong et al., 2007; Hempel et al., 2007; Sharifi et al., 2007; Turley et al., 2007; Finger et al., 2008; Gordon et al., 2008) . We and others have previously identified that TbRIII loss promotes decreased cell responsiveness to TGF-b signaling, an important step in tumor progression (Copland et al., 2003; Stenvers et al., 2003) . These findings suggest a tumor suppressor role for TbRIII in normal cells, which is further supported by studies in which restoring TbRIII expression resulted in decreased migration, invasion (Copland et al., 2003; Dong et al., 2007; Turley et al., 2007; Finger et al., 2008) and increased apoptosis (Margulis et al., 2008) in vitro and decreased tumorigenesis and metastasis in vivo (Copland et al., 2003; Dong et al., 2007; Turley et al., 2007; Finger et al., 2008) . Mechanistically, TbRIII signals through the p38 MAPK pathway to induce apoptosis (Margulis et al., 2008) and through activation of Cdc42 (Mythreye and Blobe, 2009 ) and inhibition of the NF-kB signaling pathway (You et al., 2009) to inhibit cell migration.
The GATA protein family can be divided by body distribution. GATA1-3 are primarily expressed in hematopoietic cells, whereas GATA4-6 are expressed in endoderm-derived tissues (Ho and Pai, 2007) . GATA3, a protein essential for regulating Th2 development and function, is expressed during human kidney embryogenesis (Labastie et al., 1995) with GATA3 haploinsufficiency responsible for hypoparathyroidism, sensorineural deafness and renal anomalies syndrome in humans (Van Esch et al., 2000) . Recent investigations show that GATA3 maintains differentiation in mammary gland ductal cells (Kouros-Mehr et al., 2006) and that GATA3 expression loss strongly predicts poor clinical outcome, high tumor grade and large tumor size in breast cancer patients (Mehra et al., 2005) . In human ccRCC patient samples, protein and mRNA expression of GATA3 decreases compared with normal renal tissue (Tavares et al., 2008) . Abnormal GATA3 expression is also observed in human pancreatic cancer with GATA3 expression localized to the cytoplasm of the cancer cells (Gulbinas et al., 2006) .
Our examination of TbRIII expression levels in all stages of ccRCC compared with normal patient-matched tissues shows that TbRIII expression loss occurs at all stages of ccRCC (localized and metastatic) and this loss is not due to methylation. We cloned and identified a specific promoter region governing TbRIII gene expression and identified GATA3 as a transcription factor that has a positive role in the expression of TbRIII mRNA in normal renal and ccRCC cells. We also found decreased GATA3 expression in all stages of ccRCC, partially due to methylation silencing of the gene. Our results identify GATA3 as a transcription factor, whose loss in ccRCC is responsible for the loss of TbRIII expression. These findings have important biological consequences as reexpression of TbRIII in ccRCC leads to apoptosis by activation of phosphorylated p38.
Results

TbRIII expression is lost in ccRCC
Using real-time PCR analysis, we analyzed TbRIII expression in a cohort of 10 patient-matched normal renal and ccRCC-matched samples per stage (1-4) ( Figure 1a ). We identify that TbRIII expression loss is an early event in ccRCC and remains downregulated in all stages of ccRCC. We also analyzed TbRIII expression in cell lines previously created from patient-matched normal and ccRCC tissue samples (Figure 1b) . A 67% TbRIII expression decrease was observed in stage 1 ccRCC cells (UMRC6) compared with normal-matched renal cells (NK6). Overall, 90% expression loss and greater was observed in stage 3 (UMRC5 and UMRC7) and stage 4 cells (UMRC2). Owing to limited passage potential of normal renal cells (NKs), we analyzed TbRIII expression loss in UMRC2s compared with human embryonic renal cell line HEK293 and showed a comparable expression loss. These results identify loss of TbRIII as an early event in ccRCC.
Loss of TbRIII is associated with decreased responsiveness to TGF-b signaling We evaluated TbRIII-dependent function in normal and ccRCC cells by examining Smad-dependent transcription ( Figure 1c ). Normal renal cells infected with lentiviral TbRIII short hairpin RNA compared with non-target short hairpin RNA-infected controls lead to greater than 60% attenuation of luciferase activity in cells transiently transfected with CAGA12/luciferase (Smad 2/3 reporter). TbRIII mRNA expression levels were reduced by 60% in TbRIII short hairpin RNA cells compared with non-target-infected controls (data not shown). Addition of a pan-TGF-b-neutralizing antibody or exposure to LY2109761, a TGF-b receptor I/II kinase inhibitor, decreased luciferase activity to 70 and 90%, respectively (Figure 1c ). These results show that loss of TbRIII leads to decreased responsiveness of cells to endogenous TGF-b signaling.
Methylation and histone deacetylase inhibitors restore TbRIII mRNA expression in ccRCC cells Partial cloning and characterization of the human TbRIII gene promoter has been previously described (Hempel et al., 2008) . The promoter contains two transcription start sites and three 5 0 untranslated regions (5 0 UTR). The sequence flanking the 5 0 UTR C is designated as the distal promoter (45 kb upstream of the ATG start site; 30739-34075 bp GenBank accession no. AC114486.2) and the region flanking the 5 0 UTR A the proximal promoter (25 kb from ATG) (Figure 2a ). Real-time PCR primer and probe sets were designed for 5 0 UTR A, B and C allowing for identification of the active TbRIII gene promoter. Real-time analysis of 5 0 UTR B and C showed little to no expression in the UMRC2 stage 4 ccRCC cell line ( Figure 2b ) and no expression was observed in all of the patient-matched normal renal and cancer samples at any stage of RCC (n ¼ 40). Expression of 5 0 UTR A, the proximal promoter, was present in UMRC2 cells (Figure 2b ).
Previous investigations examining prostate cancer suggest that epigenetic silencing affects TbRIII expression loss (Turley et al., 2007) . We treated UMRC2 cells with the methyltransferase inhibitor 5-aza-2 0 -deoxycytidine and/or the pan-histone deacetylase inhibitor trichostatin A (TSA) using treatment protocols as previously published . Pre-exposure of cells to 5-aza-2 0 -deoxycytidine before TSA treatment induced a robust re-expression of the distal promoter and increased proximal promoter transcript expression (Figure 2b ). Basal expression levels of the promoters imply that TbRIII expression is governed by the proximal promoter: no expression of the distal promoter 
TbRIII gene is not methylated
We examined TbRIII gene methylation status in five patient-matched tissue samples and three RCC cell lines. We were unable to detect TbRIII gene methylation in any of these samples ( Figure 2c ). Real-time PCR analysis of patient-matched samples from all ccRCC stages revealed a similar expression loss of the proximal promoter ( Figure 3a ) compared with TbRIII gene analysis in the same patient samples ( Figure 1a ). These expression similarities prompted further investigations of the proximal promoter using a luciferase reporter assay.
The full-length proximal promoter luciferase construct (À559/ þ 60) was transfected into HEK293 and UMRC2 cells identifying high luciferase activity in HEK293 cells compared with UMRC2s ( Figure 3b ). Deletions of the promoter identified that an enhancer element was present between bases À559 and À459 from the proximal transcriptional start site, as seen by the loss of activity in both transfected cell lines (Figure 3b ). Rescue of promoter activity after deletion of the À459/ À359 region suggests that a negative regulator of TbRIII has been removed with this region and that other yet to be discovered transcription factors are then able to positively regulate the remaining promoter sequence. Further deletions within the À559/À459 region of the proximal promoter identified the enhancer element located between base À559 and À534 of the proximal transcriptional start site (Figure 3c ). Potential transcription factor-binding sites were identified using the web-based TFSEARCH (http://www.cbrc.jp/ research/db/TFSEARCH.html) and a threshold score of 75% (Figure 3c ). All identified transcription factors bind to a similar inner core sequence within the À559/ À534 proximal promoter region. Deletions and mutations within this area were created and expression analyzed in HEK293 and UMRC2 cell lines.
Deletion of the À549/À539 TbRIII proximal promoter region resulted in complete luciferase expression loss in HEK293 cells and reduced expression in UMRC2s, verifying that the 10-base pair core region contains the TbRIII proximal promoter activation element (Figure 3c ). Using TFSEARCH, mutations within this region negated all identified putative binding sites and demonstrated substantial expression loss of the TbRIII proximal promoter in both cell lines, further verifying that the À549/À539 region contains putative transcription factor-binding site(s) responsible for the promoter's expression.
GATA3 binds to the À559/À534 region of the TbRIII proximal promoter One of the putative transcription factors identified within this region was that of GATA3. Transient transfection of GATA3 and the À559/ þ 60 TbRIII proximal promoter in HEK293 and UMRC2s revealed upregulation of luciferase reporter activity (Figure 4a) . We further analyzed GATA3 as a putative transcription factor interacting with the À559/À534 TbRIII proximal promoter region by electrophoretic mobility shift assay techniques using a biotin-labeled probe corresponding to this 25-bp region. Addition of HEK293 nuclear extracts to this probe produced multiple protein bands bound to this region ( Figure 4b , lanes 2, 3, 7 and 8).
Competition for binding using excess non-biotin-labeled probe demonstrates loss of all bands (Figure 4b , lane 4). Addition of a non-biotin-labeled GATA3 consensus sequence in excess, or an antibody specific for GATA3 identified a single, specific band whose intensity was decreased by these treatments (Figure 4b , lanes 5 and 6, respectively), indicative of specificity for GATA3 binding.
Nuclear extracts from UMRC2s demonstrate decreased intensity of the GATA3-specific band (Figure 4b , lane 9 compared with lane 8). When UMRC2 cells are treated with TSA and 5 0 AZA, the GATA3 band is restored (Figure 4b , lane 10). Addition of excess cold GATA3 oligonucleotide consensus sequence reduced the band intensity ( Figure 4b , lanes 11). Thus, GATA3 can bind to the 25-bp region of the TbRIII proximal promoter in normal and ccRCC cells.
GATA3 expression loss in ccRCC
A recent publication showed GATA3 mRNA downregulation in all stages of ccRCC (Tavares et al., 2008) . Analysis of our 10 patient-matched normal and ccRCC tissues by real-time PCR further confirms that GATA3 expression is lost in early-stage ccRCC (stage 1) and is also downregulated in all other stages (Figure 5a ). These finding were confirmed in experimental cell lines comparing stages 2 and 4 UMRC cells with expression levels of GATA3 in the HEK293 cells (data not shown). Tissue-matched arrays for all stages of RCC were analyzed for GATA3 expression after immunohistochemical staining showing loss of intense GATA3 staining (3 þ ) in ccRCC compared with normalmatched samples (Figure 5b ).
GATA3 expression loss in ccRCC through epigenetic changes
We examined GATA3 genes methylation status in five patient-matched tissue samples and three RCC cell lines. In all samples, the GATA3 gene was methylated but was more strongly methylated in tumor samples (Figure 5c ). Results were confirmed by bisulfite genomic sequencing (Figure 5c ), determining that methylation of DNA is having a role in the loss of expression of GATA3 in ccRCC. In contrast, bisulfite genomic sequencing determined that DNA methylation was not a cause of TbRIII expression loss in ccRCC (Figure 5c ). Treatment of UMRC2s with 5 0 AZA or 5 0 AZA plus TSA dramatically upregulates GATA3 mRNA (Figure 5d ), similar to the re-expression of TbRIII mRNA (Figure 2 ). These findings identify loss of GATA3 in all stages of ccRCC and that this loss of expression is in part due to epigenetic silencing of the gene. 
GATA3
Lane 7 1 2 3 4 5 6 8 91 011 Figure 4 hGATA3 is identified as a transcriptional factor positively regulating TbRIII mRNA by the TbRIII proximal promoter.
(a) The TbRIII proximal promoter construct (À559/ þ 60 luciferase), TK renilla luciferase, human GATA3 or an empty expression vector control were transiently transfected into HEK293 and UMRC2 cell lines as described in Materials and methods section. After collection, cell lysates were analyzed for firefly luciferase activity and normalized to TK renilla luciferase. Results are expressed as mean±s.d. (*Po0.05 Student's t-test). (b) Electrophoretic mobility shift assay analysis was performed on nuclear extracts from HEK 293 and UMRC2 cells as described in the Materials and methods section to identify transcriptional factor(s) binding to the first 25 bp sequence of the TbRIII proximal promoter. Incubation with a non-biotin-labeled GATA3 consensus oligo sequence or an antibody specific for GATA3 identified a single band corresponding to the GATA3 DNA-binding complex. 293 nuclear extracts were used as a control to identify loss of GATA3 binding in UMRC2 cells compared with 293 nuclear extracts and TSA/5 0 AZA-treated UMRC2 cells.
between GATA3 and TbRIII (Figure 6a ). Silencing GATA3 in HEK293 cells using five different lentiviral short hairpin RNAs against different GATA3 gene regions led to concomitant downregulation of TbRIII mRNA ( Figure 6b ) and GATA3 protein levels (Figure 6c) . Furthermore, this decrease in mRNA expression of GATA3 in HEK293 cells lead to decreased expression of TbRIII protein (Figure 6c ). This loss of GATA3 expression disrupts Smad signaling as identified by the CAGA12/luciferase reporter assay. This disruption of TGF-b signaling is mediated through the loss of TbRIII, as re-expression of TbRIII rescues this phenotype (Figure 6d ). Repeated attempts to stably re-express GATA3 in ccRCC cell lines have resulted in cell death with no observed upregulation of GATA3 protein expression in the remaining viable cell population. We take this data to indicate that re-expression of GATA3 is lethal to ccRCC cells. In light of our previous publication demonstrating that re-expression of TbRIII leads to massive apoptosis by a p38 MAPK-mediated pathway (Margulis et al., 2008) , this new finding is predictable. These results identify that loss of GATA3 downregulates TbRIII mRNA and protein expression leading to decreased TGF-b signaling responsiveness mediated through TbRIII.
Discussion
We identify GATA3 as the first transcription factor known to positively regulate human TbRIII mRNA and protein expression. This is also the first demonstration of the molecular mechanism for the attenuation of TbRIII in ccRCC. We found that TbRIII expression loss is not due to direct gene methylation but by methylation of the transcription factor regulating TbRIII mRNA. Our data uniquely indicates that TbRIII gene expression regulation in the human kidney is through the proximal promoter and that the distal promoter is silenced in normal and tumor tissues. We also mapped the proximal promoter region that confers TbRIII transcription regulation by GATA3. Finally, Although little is known about the regulation of the human TbRIII promoter, the mouse TbRIII promoter is positively regulated by retinoic acid and the myogenic differentiation factor MyoD (Lopez-Casillas et al., 2003) and prostaglandin E2 increases expression of TbRIII in rat osteoblasts (McCarthy et al., 2007) . Our group was the first to clone the human TbRIII promoter (Hempel et al., 2008 ) and now we identify that, in normal renal cells, TbRIII expression is governed by its proximal promoter and the area of positive gene regulation is within the À559/À534 bp promoter region. These combined data suggest that negative and positive regulatory sites exist within TbRIII's proximal promoter (Hempel et al., 2008) . This is supported by our proximal promoter deletion data that shows a negative regulatory element in the À459/ þ 60 to À359/ þ 60 region; deletion of this region leads to re-expression of the promoter, but not back to the levels observed with the full-length promoter. We have identified the positive regulator of TbRIII expression within normal renal cells as the transcription factor GATA3. Loss of GATA3 leads to decreased TbRIII mRNA and protein expression.
As GATA3 is expressed in the developing human embryonic kidney, and is shown to be expressed in normal renal proximal tubules, the proposed cell type of origin for ccRCC, this would suggest GATA3 has a yetto-be-described role in normal kidney cell function and/ or maintenance. In developing mammary glands, GATA3 has been identified as necessary for differentiation and development of luminal cells (Kouros-Mehr et al., 2008b) . Loss of GATA3 expression in the nephric duct of the developing kidney leads to aberrant cellular proliferation and elongation of the nephric duct (Grote et al., 2006) GATA3 regulates human TbRIII expression SJ Cooper et al GATA3 in late breast carcinogenesis mouse models stimulated cellular differentiation and suppressed tumor dissemination (Kouros-Mehr et al., 2008a) . Within our data, we show high expression of GATA3 in normal renal patient samples compared with low levels of expression in matched tumor samples. This loss of expression of GATA3 is an early event in ccRCC and correlates with loss of TbRIII within patient-matched samples, which we have identified to be governed by GATA3s transcriptional regulation of the TbRIII proximal promoter. Previous findings from our group have identified that re-expression of TbRIII in ccRCC induces apoptosis mediated by the p38 MAPK signaling pathway (Margulis et al., 2008) . We can therefore hypothesize that loss of GATA3 expression by methylation of the gene in normal renal cells is able to induce aberrant cell proliferation, whereas loss of TbRIII allows escape of these cells from apoptosis. However, even though GATA3 has been identified to have a role in the developing kidney, nothing is known about the role of GATA3 in adult normal kidney, much less the role of GATA3 in ccRCC carcinogenesis and progression. Loss of GATA3 expression in the kidney may lead to de-differentiation of normal renal cells as well as decreasing TbRIII expression leading to loss of TFG-b responsiveness. In general, TGF-b/Smad 2/3 signaling promotes differentiation and apoptosis in epithelial cells (Massague, 2008) . Our findings suggest that loss of GATA3 is an early event in the onset of ccRCC, an event that leads to loss of TbRIII expression and subsequent loss of TGF-b regulation. Treatment of ccRCC cells with a methyltransferase inhibitor and a pan-histone deacetylase inhibitor induces GATA3 re-expression, which in turn regulates expression of TbRIII hypothetically leading to activation of the p38 MAPK pathway and inducing apoptosis within these cells (Margulis et al., 2008) . This would suggest that GATA3 should be investigated as a novel molecular target for ccRCC therapies. Current work is directed at identifying mechanisms to selectively re-express GATA3 within ccRCC cells and to identify pathways and cellular processes that are governed by this transcription factor.
Materials and methods
Cell culture UMRC2 cells were maintained in high glucose Dulbecco's modified Eagle's medium containing 10% heat-inactivated fetal bovine serum and 1% penicillin-streptomycin-amphotericin B. HEK293 cells were maintained in aMEM supplemented with 10% heat-inactivated fetal bovine serum, 1% penicillin-streptomycin-amphotericin B, non-essential amino acids, sodium pyruvate and sodium bicarbonate. Cell lines were cultured at 37 1C and 5% CO 2 . UMRC2, UMRC3, UMRC5, UMRC6 and UMRC7 ccRCC cell lines and patientmatched NK2, NK5, NK6 and NK7 normal human primary renal epithelial cells were a kind gift from Dr E Barton Grossman, UT MD Anderson Cancer Center.
To investigate 5-Aza-2 0 -deoxycytidine's and/or TSA's effect on reversing gene silencing, cells were treated with either dimethylsulfoxide for 4 days, dimethylsulfoxide for 4 days with the last 16 h combined with TSA (histone deacetylase inhibitor 0.5 mM), 4 days 5-Aza-2 0 -deoxycytidine (10 mM) with the last 16 h combined with dimethylsulfoxide or 4 days 5-Aza-2 0 -deoxycytidine (10 mM) combined with TSA (0.5 mM) for the final 16 h.
RNA extraction and real-time PCR Cellular RNA was extracted from UMRC2 and HEK293 cells using the RNAqueous-Midi Kit (Ambion, Austin, TX, USA) per the manufacturer's instructions. This purified RNA was reversed transcribed with the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Austin, TX, USA) using provided random primers. For subsequent real-time PCR quantifications, 20 ng of template cDNA were used per reaction. Applied Biosystems' assays-on-demand 20 Â primers and Taqman MGB probes for TbRIII (Hs00234257_m1), GATA3 (Hs00231122_m1), glyceraldehyde-3-phosphate dehydrogenase (Hs99999905_m1) and 18S (Hs99999901_s1) were used for real-time PCR. Forty cycles were undertaken on the Applied Biosystems 7900HT Fast Real Time PCR System. Samples were normalized to either 18S or glyceraldehyde-3-phosphate dehydrogenase and DDC t methods used to calculate fold expression changes of mRNA (Livak and Schmittgen, 2001) . For real-time PCR, 200 ng of cDNA was used with the ThermalAce DNA polymerase kit (Invitrogen, Carlsbad, CA, USA) as per the manufacturer's instructions. Primers were designed using the GenBank accession no. AY796304.1 TbRIII sequence at locations 1360À1379 bp (5 0 UTRC), 7606-7627 bp (5 0 UTRB), 21286-21304 bp (5 0 UTRA) and 45728-45747 bp (reverse primer); 5
(5 0 UTRA) and 5 0 -CGTCTCGTCCAGTCACTTCA-3' (TBRIII promoter reverse primer). Samples were amplified for 35 cycles and visualized by electrophoresis using a 1.5% agarose gel containing ethidium bromide (Invitrogen).
Lentiviral infection
Lentiviral constructs to package self-inactivating lentiviruses were made in the pLKO.1 vector (Sigma-Aldrich, St Louis, MO, USA). We purchased lentiviruses from the human clone set NM_002051 for GATA binding protein 3 from SigmaAldrich and a random scrambled sequence was used for the non-target vector. Target renal cells were plated in 10 cm plates and grown to 70% confluence before infection along with 7.5 mg/ml polybrene, as per the manufacturer's protocol. Infected cells were selected using 2.5 mg/ml puromycin (Sigma-Aldrich).
Genomic DNA isolation Patient samples were collected and processed by this laboratory as previously described in accordance with Institutional Review Board protocols (Gumz et al., 2007) . Patient-matched human RCC and normal tissue collected from distant cortex, along with several cell lines, were lysed for genomic DNA isolation using the Aquapure Genomic DNA Isolation Kit (Bio-Rad, Hercules, CA, USA), according to the manufacturer's instructions.
Microarray gene array analyses
Microarray gene expression data on GATA3 and TbRIII in 10 early stage ccRCC samples (five stage 1 and five stage 2 ccRCC) and 10 tumor-matched normal renal samples were analyzed as previously described (Gumz et al., 2007) .
Methylation-specific PCR and bisulfite genomic sequencing Methylation status of GATA3 and TbRIII genes in human RCCs, their matched normal control tissues and RCC cell lines were first tested with methylation-specific PCR as previously described (Gumz et al., 2007 Methylation status of representative samples was confirmed by bisulfite genomic as previously described (Gumz et al., 2007) . Bisulfite genomic sequencing primer sequences and annealing temperatures were 5 0 -GTTGGGTGAGTTATTAT TATTT-3 0 (sense) and 5 0 -ATATTAAAAAACACATCCACC TC-3 0 (antisense) for GATA3 at 56 1C, and 5 0 -GTTTTTTG TAGGAGGTGAGAG-3 0 (sense) and 5 0 -CAACCTACAAAA CCCACAAC-3 0 (antisense) for TbRIII at 60 1C.
Antibodies and western blot analyses
Cell lysates were collected, quantified and transferred to Immobilon-P membrane as previously described (Copland et al., 2006) . Membranes were hybridized with mouse anti-GATA3 (Santa Cruz Biotechnology, Santa Cruz, CA, USA) or rabbit anti-TbRIII (R&D Systems, Minneapolis, MN, USA) overnight at 4 1C before treatment with species-specific horseradish peroxidase immunoglobulin-G antibodies (Jackson Laboratory, West Grove, PA, USA) for 45 min at room temperature. Detection was performed using enhanced chemiluminescent detection substrate (Amersham Pharmacia Biotech, Piscataway, NJ, USA).
Promoter deletion constructs
Creation of the À559/ þ 60 TbRIII proximal promoter luciferase construct is previously reported (Hempel et al., 2008) . Deletions of this construct were created using the QuikChangeII Site Directed Mutagenesis Kit (Stratagene, La Jolla, CA, USA), as per the manufacturer's instructions using the primers: GATA3 deletion sense 5 0 -GGTACCGAGCTC TGCTCAAGAGGCTG-3 0 ; GATA3 mutation sense 5 0 -GGT ACCGAGCTCTGCTGGGCTTAGGGCAAGAGGCTG-3 0 ; À534 sense 5 0 -CGATAGGTACCGGCTGTGATCAGATTA TCTGAGG-3 0 ; À484 sense 5 0 -CGATAGGTACCGAACCA AATGAAAATCCAACTCTTCC-3 0 ; À459 sense 5 0 -CGATA GGTACCCAGGGAGCCCTGGAAAG-3 0 . Deletions were verified by DNA sequencing before purification with PureLink HiPure Plasmid Maxiprep Kit (Invitrogen).
Luciferase assays
Promoter constructs were transfected in triplicate (0.5 mg DNA/ well) with 10 ng/well control Renilla luciferase reporter using Fugene 6 transfection reagent (Roche, South San Francisco, CA, USA). Cells were lysed 24 h post-transfection and luciferase activity measured using the Duel Luciferase Kit (Promega, Madison, WI, USA) as per the manufacturer's instructions. For the CAGA12 assay, 24 h post-transfection cells were treated with 25 mg/ml TGF-b pan-neutralizing antibody, 25 mg/ml goat IgG control, 50 mM LY2109761 (TGF-b receptor I/II kinase inhibitor, gift from Eli Lilly and Company, Indianapolis, IN, USA) or dimethylsulfoxide vehicle control for 24 h.
Electrophoretic mobility shift assay
Oligos for the first 25 bp of the TbRIII proximal promoter were purchased (Integrated DNA Technologies, Coralville, IA, USA) with a 5 0 -end forward strand biotin label 5 0 -GAGCTCTGCTGG GGAGAGGGCAAGA-3 0 . Control oligos without biotin labeling were purchased, as was the same region of the proximal promoter with a GATA3-binding site mutation (5 0 -GAGCTCTGCTGGGC CCCGGGCAAGA-3 0 ) and a GATA3 consensus sequence (5 0 -GA CCTGAGATAGGGCGGTT-3 0 ). Nuclear extracts were isolated as previously described (Cooper et al., 2005) .
For shift assays, 1 mg of nuclear protein was incubated in 20 ml of a buffer containing 10 mM HEPES (pH 7.9), 50 mM KCl, 0.1 mM EDTA, 2.5 mM dithiotreitol, 10% glycerol, 0.05% Nonidet P-40 and 0.05 mg/ml poly (dI-dC) on ice. Unlabeled probe and/or specific antibody GATA3 sc-268X (Santa Cruz Biotechnology) were added for 45 min on ice. Biotin-labeled probe was added 20 min before gel loading. Samples were resolved on a nondenaturing 6% polyacrylamide gel in 0.25 Â TBE before transferred to a positively charged nylon membrane (Roche) in 0.25 Â TBE. Transferred DNA was crosslinked to the membrane by 120 mJ/cm 2 ultraviolet light from a Spectrolinker XL1000 UV Crosslinker (Spectronics Corporation, Westbury, NY, USA). Membranes were treated, activated and exposed to film using the LightShift Chemiluminescent electrophoretic mobility shift assay kit, as manufacturer-directed (Pierce, Rockford, IL, USA).
Immunohistochemistry
Patient-matched normal, renal and ccRCC tissue samples were treated as previously described (Gumz et al., 2007) . Sections were immunostained using an antibody against human GATA3 (1:400; IMGENEX, San Diego, CA, USA). Tissue staining intensity was graded on signal intensity (0, 1 þ , 2 þ , 3 þ grade) and percentage positive cells (0p5%, 1 þ ¼ 5-20%, 2 þ ¼ 20-50% and 3 þ X50%). If insufficient tissue existed, samples were excluded from the study. Images were obtained using a Scanscope XT (Aperio, Vista, CA, USA) and Spectrum software.
Statistical analysis
One outlier each for stages 2 and 3 patient-matched samples were observed, but removed from analysis due to the value being an extreme outlier as identified using the formula w4Q 3 þ 3(Q 3 ÀQ 1 ). Data are presented as the mean±s.d., and comparisons of treatment groups were analyzed by two-tailed equal variance Student's t-test. Data for comparison of multiple groups are presented as mean ± s.d. and were analyzed by analysis of variance. *Po0.05 was considered to be statistically significant. 
